丽珠医药(01513.HK) 公布,控股附属丽珠单抗与北京鑫康合生物医药科技司联合开发的重组抗人IL-17A/F人源化单克隆抗体注射液“LZM012”的Ⅲ期临床试验达到主要研究终点。该Ⅲ期临床研究是一项在中重度斑块型银屑病患者中开展的多中心、随机、双盲、阳性对照(司库奇尤单抗)的临床试验,研究结果显示,该研究的主要疗效终点已达到。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-07...
Source Link丽珠医药(01513.HK) 公布,控股附属丽珠单抗与北京鑫康合生物医药科技司联合开发的重组抗人IL-17A/F人源化单克隆抗体注射液“LZM012”的Ⅲ期临床试验达到主要研究终点。该Ⅲ期临床研究是一项在中重度斑块型银屑病患者中开展的多中心、随机、双盲、阳性对照(司库奇尤单抗)的临床试验,研究结果显示,该研究的主要疗效终点已达到。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-07...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.